O ncogenesis, in part, has been associated with dysregulated expression of various microRNAs (miRNAs or miRs). 1À5 Inhibition or restoration of endogenous miRs is a unique and effective strategy to restore cellular homeostasis, and is considered to be a promising new generation of molecularly targeted anticancer therapeutics. 6, 7 Recent findings support targeting miRNAs as a potentially useful antimetastatic therapeutics strategy. The antisense-miRNAs or anti-miRNAs are a novel class of chemically modified oligonucleotides of 18À22 bases used to block the functions of endogenous miRNAs that regulate various genes involved in major cellular processes, such as cell proliferation, differentiation, and apoptosis. 8, 9 Antagonizing miR-10b by antisense-miR10b has been reported to be effectively inhibited metastatic spread to the lungs, without affecting the growth of previously metastasized tumors in a mouse model of human breast cancer. 10, 11 Antisense-RNA mediated knockdown of endogenous miR-21 has been reported to impair tumor cell growth, induce apoptosis, and reduce the migration and invasion of cancer cells expressing miR-21 at high levels. 12À18 We hypothesize that antagonizing multiple endogenous miRNAs could simultaneously affect target genes of different miRNAs and result in additive or enhanced therapeutic effect. Despite improvement in the stability of sense-and antisense-miRNAs by modification of the nucleic acid structure, therapeutic sense-and antisense-miRNAs require effective delivery systems in order to become useful agents. Several delivery systems have been designed and developed to protect nucleic acids from degradation. 19À27 Cell-penetrating peptide conjugated, anti-miR-155-loaded PLGA NPs effectively inhibited endogenous miR-155 function and significantly reduced the growth of leukemia and lymphoma (pre-B-cell) tumors in vivo in mice models at the dose of 1.5 mg/kg body weight. 25 However, these
NPs showed significantly lower antitumor efficacy when the dose was reduced down to 0.5 mg/kg body weight. 25 Antisense-miR-10b-loaded polylysine NPs inhibited the invasive property of human breast cancer cells in vitro in cell culture for up to 4 weeks, as measured by the wound-healing assay. 28 MiR-29b loaded cationic lipoplexes successfully delivered miR-29b to A549 nonsmall-cell lung carcinoma (NSCLC) cells and significantly inhibited tumor growth in animals. 27 Even though most of these above-mentioned NPs were able to deliver sense-and antisense-miRNAs and achieve different levels of functional effect, specific delivery of miRNA-based therapeutics to tumor cells in vivo remains a challenge due to degradation of miRNAs by serum nucleases, off-target effects, poor cellular uptake, and rapid renal clearance after administration. 29 In addition, poor miRNA loading efficiency is another major limiting factor, which necessitates the injection of higher percentage of carrier for miRNAs delivery that in turn causes carrier associated toxicity. Moreover, the miRNAs release profile from NPs and the stability of NP loaded miRNAs in serum at physiological conditions are other important phenomena lacking experimental support in the literature, but are essential to address for optimal in vivo delivery. To advance beyond current strategies, serum stable, tumor targeted, improved delivery systems with higher loading efficiency and sustained-release properties for miRNAs are much needed. NPs synthesized from a synthetic polymer, PLGA, have been extensively studied for anticancer drugs delivery. 22, 30 Compared to most other types of delivery systems, PLGA has many advantages, such as (1) FDA approved for drug delivery in humans, 31, 32 (2) biodegradability, (3) sustained-release efficacy ranging from days to weeks in physiological conditions, (4) longterm stability of loaded bioactive molecules, (5) the ability to entrap hydrophobic and/or hydrophilic drugs, and (6) extensive functionalization options.
22
PEG is another well-known water-soluble, biocompatible polymer extensively used for coating a wide variety of drugs to improve encapsulation efficiency, and circulation time and bioavailability in animals, that also protects NPs from immune surveillance. 22, 33 Here, we report an efficient delivery and antimetastatic and antitumor potentials of a specific combination of antisense-miRNAs or anti-miRNAs (antisense-miR-21 or anti-miR-21 and antisense-miR-10b or anti-miR-10b) utilizing NPs prepared from biodegradable PLGA-b-PEG copolymers and uPA peptide conjugated NPs targeting breast cancer specific uPA-receptor (uPAR) in triple negative breast cancer (TNBC) tumors.
RESULTS AND DISCUSSION
Nanoparticle Preparation and Characterization. PLGA-b-PEG and uPA-peptide conjugated PLGA-b-PEG-NPs loaded with antisense-miRNAs were formulated using water-in-oil-in-water (w/o/w) double emulsion method (Supporting Information (SI) Scheme S1, Figures S1ÀS2). Two different emulsifiers are crucial for w/o/w multiple emulsion stabilization, one with a low hydrophileÀ lipophile balance (HLB) for the w/o interface, and the second one with a high HLB for the o/w interface. Tween 80 (HLB = 15) is often used in combination with Span 80 (HLB = 4.3) in multiple w/o/w emulsions because of similarity in their chemical structure. 34 We used spermidine as a counterion 35, 36 for encapsulating various sense-and antisense-miRNAs (SI Table S1 ), lipophilic surfactant Span 80 for stabilizing the first emulsion (w/o), and hydrophilic surfactant Tween 80 for stabilizing the second emulsion ( Figure 1A ). Dynamic light scattering (DLS) of prepared NPs showed a size range of 100 to 200 nm ( Figure 1B ) with a polydispersity index (PDI) of 0.09À0.264. The zeta potential of NPs was in the range of À22 to À46 mV in ultrapure water (SI Tables S2ÀS3). The highly anionic nature of antisense-miRNAs should increase the negative zeta potential of NPs. As anticipated, the antisense-miRNAs loaded NPs showed much higher negative zeta potential compare to control NPs (SI Tables S2ÀS3). Morphology and size of NPs were further confirmed by transmission electron microscopy after staining with 1% phosphotungstic acid ( Figure 1C ). The entrapment efficiency of various antisense-miRNAs loaded in NPs was calculated using Quant-iT RNA Assay kit, as well as by optical CCD camera imaging based quantification for the coloaded Cy5-antisense-miR-21 after resolving the NPs by agarose gel electrophoresis ( Figure 1D ). The average number of antisense-miRNAs encapsulated in various NP formulations was estimated to be in the range of 400 to 1000 molecules/NP (SI Tables S2ÀS3). Moreover, we also evaluated the distribution of antisense-miR-21 and antisense-miR10b in the coloaded nanoparticles by qRT-PCR analysis.
The results indicate that coloading of antisense-miR-21 and antisense-miR-10b in PLGA-b-PEG-NPs is found almost at equimolar concentration in NPs prepared in different batches (SI Figure S3) . The antisense-miRNAs extracted from the equimolar mixture of NPs formulated with each antisense-miRNAs (antisense-miR-21 and antisense-miR-10b) separately was used as control.
MicroRNA Stability and Release in Cell Culture Medium. Evaluation of in vitro stability and the release of loaded antisense-miRNAs in cell culture medium and in serum are important for predicting the potential of developed ARTICLE NPs for therapeutic applications. There is not many reports available in the literature except a single report where it describes the in vitro release profile and serum stability of miRNAs loaded in protamine sulfate-nanodiamond by a semiquantitative gel electrophoresis method. 37 Since, no data available on the complete release profile and serum stability of miRNAs loaded in NPs using an absolute quantitation method, in this study, we evaluated the release profile of miR-21 loaded in PLGA-b-PEG-NPs (SI Tables S1ÀS2) using TaqMan-qRT-PCR. The results indicate that ∼4% of loaded miR-21 was released into the medium in the first 3 days, and the release was down to ∼1À2% at the later time points ( Figure 1E ,F). The reduction in the amount of miR-21 observed in the released fraction at later time points may be partially associated with the stability of released miR-21 in the medium. While the released fraction significantly dropped over time, the miR-21 fractions extracted from the NPs were significantly higher even 8 days after incubation (∼75% of initial spiked miR-21 was found in the NP-fraction) ( Figure 1E,F) . These results clearly indicate that miRNAs loaded in PLGA-b-PEG-NPs are stable in a normal growth medium for extended period of times.
MicroRNA Cellular Uptake and Serum Stability. Mitchell et al. reported that synthetic naked miRNAs are rapidly degraded in plasma compared to various endogenous miRNAs isolated from human samples. 38 It could be possibly due to protein complexes associated with the endogenous microRNAs, which are in general lacking for the delivered synthetic therapeutic miRNAs. We tested the stability of PLGA-b-PEG-NPs encapsulated miR-21 delivered in MDA-MB-231 cells and spiked in mouse serum by TaqMan-qRT-PCR analysis ( Figure 2 ). MDA-MB-231 cells were treated with miR-21 loaded PLGA-b-PEG-NPs for 24 h, and the total microRNAs extracted from the cells after a thorough wash to remove the extracellular NPs were quantitatively measured for the presence of intact miR-21 by qRT-PCR. The cells without any NP treatment, and treated with control NPs were used as controls. The results show that in cells treated with 10 and 50 pmols of miR-21-NPs, the intracellular miR-21 level was ∼836 ( 188 and ∼11322 ( 1486 fold higher, respectively, compared to controls ( Figure 2A ). The cells treated with control NPs showed a minor but not significant drop in the endogenous miR-21 level compared to untreated control. To further evaluate the endogenous basal level expression of miR-10b and miR-21, the two therapeutic Figure S7 ). Another batch of cells exposed to similar conditions was monitored at different time points for its cellular uptake, distribution and clearance for up to 120 h by fluorescent microscopy. The results show a constant increase in the NP accumulation over time up to 72 h, and the Cy5 signal started dropping slowly after 72 h (SI Figure S4 ). Dynamic uptake of Cy5-antimiR-21 loaded PLGA-b-PEG-NP was studied in MDA-MB-231 cells stably expressing Fluc-eGFP reporter fusion protein using a time-lapse microscopic imaging system under a controlled (5% CO 2 and 37°C) incubation condition for 16 h, with snapshot images taken once every 10 min. The results show that the NPuptake started as early as 30 min from the onset, and saturation was reached at around 6 h (SI Movie S1). However, we observed cell death after 16 h of incubation, which was mainly due to the instrument setup that was not optimal for prolonged incubation of cells. In another experiment, the MDA-MB-231 cells were incubated with various concentrations of PLGA-b-PEGNPs loaded with Cy5-antisense-miR-21 for 24 h, and assessed the cellular uptake of NPs by FACS analysis (SI Figure S8A) . The results show a concentrationdependent increase in the intracellular accumulation of NPs in the cells, with maximum fluorescence intensity at 25 nM. In addition, cells treated with NPs coencapsulated with Cy5-antisense-miR-21-antisensemiR10b showed similar fluorescence intensity, further confirming that the coencapsulation is not affecting the intracellular entry of Cy5-antisense-miR-21 (SI Figure S8B) .
To further test the stability of miR-21 in serum, miR-21-PS loaded in PLGA-b-PEG-NPs or equal amount of free miR-21-PS was spiked into 100 μL of mouse serum and measured for intact miR-21 at 0, 12, 24, and 48 h after incubation at 37°C. After specified incubation times, miRNA was extracted from the serum sample and analyzed for the presence of intact miR-21 by TaqMan-qRT-PCR assay. The results indicate that more than 95% of free miR-21 degraded within the first 24 h of incubation. Interestingly, more than 50% of miR-21 loaded in NPs was detected even 48 h after incubation ( Figure 2FÀH ). These results indicate that the miR-21 loaded in PLGA-b-PEG NPs was well protected from the action of serum nucleases.
Cell In Vitro Cell Growth and Invasion Studies. Since miR-10b has been mainly associated with anti-invasive and antimetastatic properties, and miR-21 has been associated with antiapoptotic property in breast cancer cells, 39, 40 we evaluated the change in cells migration and invasive property after simultaneously antagonizing miR-21 and miR-10b in MDA-MB-231 cells by using the transwell-Matrigel cell migration and invasion assay. MDA-MB-231 cells stably expressing Fluc-eGFP reporter gene was used for this assay for easy visualization and quantitation of GFP positive cells in Matrigel. The cells were treated for 48 h with the respective NPs and assayed for cell migration in Matrigel transwell chamber. We found ∼23 ( 5% reduction in cell ARTICLE migration in cells treated with NPs loaded with antisensemiR-21, and antisense-miR-10b, and coloaded with antisense-miR-21 and antisense-miR-10b as compared to control NP treated cells (SI Figure S10A) . We also found similar results when measured by wound healing assay (SI Figure S10B) . Table S4 ). The respective protein levels were measured by immunoblot analysis. An increase in ARTICLE the target protein expression was also observed in cells treated with respective antisense-miRNAs loaded NPs ( Figure 4B ). Interestingly, we observed that PTEN mRNA and protein levels increase when cells were treated with antisense-miR-10b. Similarly, confocal microscopic imaging of cells immunostained for miR-21 target PDCD4 showed higher level of PDCD4, with disintegrated nuclear structure in cells treated with NPs loaded with antisense-miR-21 and coloaded with antisense-miR-10b-and antisense-miR-21 combination, and not with control NPs or NPs loaded with antisense-miR-10b ( Figure 4C ). To further test the functional role of antisense-miRNAs in blocking the endogenous miRNAs, downregulation of miR-21-target ARTICLE genes maspin and PDCD4 were indirectly monitored in cells by expressing firefly luciferase reporter gene containing the 3 0 -UTR sequences derived from maspin or PDCD4 gene. 41 We found a significant upregulation of luciferase signal in cells treated with NPs loaded with antisense-miR-21 and coloaded with antisense-miR-21 and antisense-miR-10b combination, as compared to cells treated with NPs loaded with the scrambled antisensemiRNA or antisense-miR-10b (SI Figure S11AÀD) . Antitumor and Antimetastatic Properties of Antisense-miRNAs Delivered by PLGA-b-PEG-NPs in TNBC Tumor Xenograft in Living Animals. The growth, metabolic rates, and the metastatic properties of tumor cells, in response to the treatment of PLGA-b-PEG NPs loaded with and without antisense-miRNAs were measured in living mice by optical bioluminescence imaging. Subcutaneous tumor xenografts of MDA-MB-231-Fluc-eGFP cells were established on either side of the lower flanks of nude mice. One group of animals (n = 5) was implanted with cells pretreated for 48 h with control PLGA-b-PEG-NPs, and the second group (n = 5) was implanted with cells pretreated for 48 h with PLGA-b-PEG NPs coloaded with antisense-miR-21, Cy5-antisensemiR-21 and antisense-miR-10b combination. Animals were imaged every other day by optical CCD camera for bioluminescence signal and tumor volume measure using digital Vernier caliper. The results demonstrate that growth of tumors established by cells pretreated with NPs coloaded with antisense-miR-21 and antisense-miR10b combination was significantly slower (∼35 ( 10%; p < 0.05) when compared to tumors implanted from cells pretreated with control NPs (SI Figure S12A,B) . The aim of this part of the study was to test the sustained release of functional antisense-miRNAs by the delivered NPs. To confirm the sustained release and the presence of delivered antisense-miRNAs in cells, the animals were imaged by fluorescence imaging for the presence of the coloaded Cy5-antisense-miR-21. A significant amount of Cy5-signal was visualized in the tumors even 8 days after the implantation of tumor (SI Figure S13) . Three weeks after repetitive imaging, the tumors were collected and analyzed ex vivo for tumor tissue architecture by H&E staining, and for tumor cell apoptosis by TUNEL assay. The results show a significant amount of apoptotic cells in the tumors of animals implanted with cells pretreated with NPs coloaded with the antisense-miR-21 and antisense-miR-10b combination, as compared to control NPs treated cells (SI Figure S14) .
To confirm the downregulation of endogenous miR-21 and miR-10b function in tumor cells owing to the delivery of antisense-miR-21 and antisense-miR-10b coloaded NPs compared to control NPs, and to study their effect on regulation of tumor cell metastasis, 1 Â Figure S15) . The results indicate that in both groups the tumor growth showed no significant difference from Day 0 through Day 4. However, starting from Day 6 onward, in the saline treated group the tumor growth rapidly increased compared to animals treated with antisense-miRNAs coloaded NPs. The bioluminescence imaging signals measured from these animals correlated with the tumor volumes (SI Figure S15AÀC) .
Antitumor Effect of Systemically Delivered Urokinase Plasminogen Activator Receptor (uPAR) Targeted PLGA-b-PEG-NPs Coloaded with Antisense-miR-21 and Antisense-miR-10b Combination in Living Animals. In this section we further evaluated the therapeutic effect of systemically injected PLGA-b-PEG-NPs coloaded with antisense-miRNAs in TNBC tumor xenografts in nude mice. We used uPA peptide conjugated PLGA-b-PEG-NPs targeting tumor specific uPAR receptor to efficiently deliver ARTICLE antisense-miRNAs at increased amounts, in addition to NPs delivered to tumors through inherent enhanced permeabilization and retention (EPR) effect. We used PLGA-b-PEG-NPs conjugated with scrambled (sc or scrb)-uPA peptide and coloaded with antisense-miR-21 and antisense-miR-10b combination as matched control. The PLGA-b-PEG copolymers were conjugated with uPA and scrambled-uPA peptides using standard chemistry (SI Scheme S1), and the conjugation was confirmed by 1 H NMR and MALDI-TOF mass spectrometry (SI Figures S1ÀS2) . The NPs prepared using PLGA-b-PEG copolymers with uPA and Scrambled-uPA were loaded with antisense-miR-21 and antisense-miR-10b individually and in combinations (SI Table S3 ). The NPs were first tested for the loaded antisense-miRNAs delivery and functional effect in MDA-MB-231 cells in culture by treating with 25 pmols of each antisense-miRNAs. The results show significant antiproliferative effect in cells treated with uPA and Scrb-uPA conjugated PLGA-b-PEG-NPs coloaded with antisense-miR-21 and antisensemiR-10b combinations compared to cells treated with other NPs (SI Figure S16 ). The cells treated at similar conditions for 36 h were used for evaluating the functional effect of delivered antisense-miRNAs on target genes expression (PDCD4 and HoxD10) by TaqMan qRT-PCR. The results indicate that the mRNA level of miR-21 target PDCD4 increased when cells were treated by NPs loaded with antisense-miR-21 (uPAantisense-miR-21, uPA-antisense-miR-21-antisense-miR10b and Sc-uPA-antisense-miR-21-antisense-miR-10b), compared to control and NPs loaded with antisensemiR-10b (SI Figure S17A) . In contrast, HoxD10, the target of miR-10b, expression increased in cells treated by NPs loaded with antisense-miR-10b (uPA-antisense-miR-10b, uPA-antisense-miR-21-antisense-miR-10b and Sc-uPAantisense-miR-21-antisense-miR-10b) (SI Figure S17B ). Since these in vitro results confirmed the functional efficiency of the synthesized targeted NPs, we used them for antitumor studies in animals for systemic delivery experiments.
The antitumor effect of systemically injected uPAR targeted NPs loaded with different combination of antisense-miRNAs was studied in tumor xenografts of MDA-MB-231 cells stably expressing Fluc-eGFP reporter fusion gene. The targeted delivery of NPs loaded with antisense-miR-21 and antisense-miR-10b, and coloaded with antisense-miR-21 and antisense-miR-10b combination, injected at 0.15 mg/kg, was measured for tumor size and bioluminescence imaging signal over time. The scrambled-uPA-peptide conjugated PLGA-b-PEG-NPs coloaded with antisense-miR-21 and antisensemiR-10b, and control PLGA-b-PEG-NPs injected animals served as controls. The mouse TNBC tumor xenograft model was developed by injecting 0.1 mL of MDA-MB-231-Fluc-eGFP cell suspension (10 Â 10 6 ) into the left and right flanks of female nude mice (Nu/Nu) using 50% (v/v) Matrigel. After 15 days, when the tumors size reached 100À300 cubic mm, the animals [n = 25, 5 animals with two tumors each (n = 10 for each treatment group) for each treatment group] were intravenously injected with the NPs on Day 0, Day 3, and Day 6 ( Figure 5A ). The tumor development and growth was monitored over time (up to Day 9) by measuring tumor volume and bioluminescence imaging. After the completion of imaging on Day 9, the tumors were excised for ex vivo histological analysis. The results indicate that the tumor growth of animals treated by NPs loaded with both antisense-miR10b and antisense-miR-21 individually and in combinations showed significant reduction in tumor growth, compared to control-NPs treated animals, with highest effect being detected in animals treated by uPAÀ PLGA-b-PEG-NPs coloaded with antisense-miR-10b and antisense-miR-21 combinations. The antisense-miR-21-10b coloaded-uPA NPs treated mice shows 40% more tumor reduction compared to antisense-miR-21-10b coloaded NPs with scrambled-uPA, signifying the uPA targeting effects on MDA-MB-231 tumors ( Figure 5A ). The bioluminescence imaging signal also showed similar level of signal drop in animals treated with antisensemiRNAs loaded NPs compared to control-NPs treated group ( Figure 5A-C) . The ex vivo analysis of kidney and liver tissues showed no sign of toxicity in animals treated by NPs with or without antisense-miRNAs (SI Figure  S18AÀC) . The ex vivo TUNEL staining of tumor tissues showed significant amount of apoptotic cells in animals treated with antisense-miRNAs loaded NPs, with the highest level being detected in animals treated with uPA-targeted NPs coloaded with both antisense-miR10b and antisense-miR-21 combination ( Figure 5D , SI Figure S18D ).
In this study we successfully developed and optimized protocols for encapsulating antisense-miRNAs in PLGA-b-PEG-NPs with higher loading efficiency compared to previously reported methods. 22, 35, 42 The resulted NPs can be potentially used for achieving prolonged therapeutic efficiency with lower dose with minimum off target toxicity. The antisense-miRNA targets selected in this study for inhibitions are the widely studied miR-21 and miR-10b. The role of miR-21 12À18,43 and miR-10b 10, 11, 39, 43 in tumor growth, invasion, metastasis, and drug resistance in breast cancer is well-documented. 11, 44 However, the utility of antisense-miRNAs in therapeutic intervention is largely dependent on effective delivery and sustained efficacy of the internalized antisense-miRNAs following treatment. Systemically delivered miRNAs require an efficient system of ensuring intracellular transport, specificity, and metabolic stability to succeed as therapeutic options.
The synthesized PLGA-b-PEG-NPs in cell viability studies indicate an absence of significant toxic effects at relatively high concentrations of NPs. Simultaneous codelivery of antisense-miR-21 and antisense-miR-10b combinations in cell migration, metastasis, and invasion ARTICLE assays show a significant and incremental decrease in motility and invasiveness in vitro, and also indicates a cumulative effect in reducing TNBC xenograft tumor growth in animals. The sustained release of antisensemiR-21 and antisense-miR-10b from delivered NPs over 15 days achieved an approximately 40% reduction in tumor growth in animal model, and a mouse metastasis model indicated a significant decrease in lung and organ metastasis following treatment.
Targeted delivery of drugs and small RNAs loaded in NPs can overcome problems displayed by naked small RNAs and free drugs, comprising poor serum stability, lack of selectivity, and rapid renal clearance after administration, which leads to nonspecific toxicity to normal cells and constrains adequate dose administration to eliminate the cancer cells. 21 The uPAR has been recognized to be involved in multiple steps in cancer progression. 45 We synthesized the uPAR targeting peptide conjugated, antisense-miR-21 and antisense-miR-10b coloaded, PLGA-b-PEG-NPs. We envisioned that PEGylation of PLGA would increase the circulation time of NPs, owing to EPR effect in mice and uPA peptide targeting the tumor cells. Our results indicated that the uPA peptide conjugated NPs efficiently delivered the antisense-miRNAs and achieved highest tumor reduction in animals where NPs codelivered antisense-miR-21 and antisense-miR-10b combination, whereas scrambled NPs treated mice showed 40% less tumor reduction compared to uPAR targeting NPs. We consider that significant tumor reduction in animals treated with scrb-NPs is because of the EPR effect of PEG group in the NPs.
CONCLUSION
In summary, we have successfully developed an efficient protocol for coloading antisense-miRNAs in PLGA-b-PEG-NPs. The simultaneous delivery of antisensemiR-21 and antisense-miR-10b has a cumulative effect in reducing breast cancer cell proliferation in vitro in culture and in vivo tumor xenografts. The sustained release of antisense-miR-21 and antisensemiR-10b from NPs over 15 days achieved a 40% reduction in tumor growth in animal model. These results suggest that antagonizing multiple miRNA activities 
ARTICLE
could be an efficient and enhanced therapeutic strategy to block metastatic properties of tumor cells, in addition to inducing apoptosis, in cancer therapy. Targeted delivery of NPs showed a substantial reduction in tumor growth at very low dose of antisensemiRNAs (0.15 mg/kg), compared to the control NPs, and 40% reduction in tumor growth compared to scrambled peptide conjugated NPs treated mice, suggesting a potential therapeutic strategy for TNBC tumors. This strategy can be combined with other therapeutic drugs to achieve improvement in chemotherapy at lower doses of drugs. Further studies are in progress to study the effects of therapeutic drugs and miRNAs coloaded NPs in breast tumors.
MATERIALS AND METHODS
Materials. All chemical reagents used for the study were of analytical grade or above. Poly(D,L-lactide-co-glycolide) (50/50) with acid terminated (PLGA, inherent viscosity 0.16À0.24 dL/g, MW 7000À17 000), 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), 4-dimethylaminopyridine (DMAP) and diisopropylethylamine (DIPEA) were obtained from Sigma-Aldrich (St. Louis, MO, USA). NH 2 -PEG-COOH (MW 3400) was purchased from JenKem Technology, USA (Allen, TX) and NOF Corporation, USA (Irvine, CA). AntisensemiRNAs were custom synthesized by PAN Facility at Stanford, at purity above 90% (SI Table S1 for sequences of miRs and antisense-miRNAs with various modifications). Urokinase plasminogen activator receptor (uPAR) targeted uPA-peptide (VSNKYFSNIHWGC) and scrambled (sc or scrb) peptide (SGLITPGILPIHGCSF) were synthesized using solid phase peptide synthesizer (CS Bio Company Inc., Menlo Park, California).
Synthesis of PLGA-b-PEG-COOH Polymer. To activate acid terminated PLGA, a solution of PLGA (500 mg) in dry dichloromethane (DCM) (5 mL), N-hydroxysuccinimide (NHS) (80 mg) and 1-ethyl-3-[3-(dimethylamino)propyl] carbodiimide (EDC) (48 mg) were combined at room temperature and stirred for 4 h. The reaction mixture was then added dropwise into cold diethyl ether/MeOH (1:1) (40 mL), and the resultant precipitate was centrifuged (5000 rpm for 5 min), the supernatant was decanted, and the resulted pellet was further washed (three times). The precipitate of PLGA-NHS was dried at high vacuum overnight. The PLGA-NHS (360 mg) and HCl-NH 2 -PEG-COOH (102 mg) were dissolved in chloroform (5 mL), and diisopropylethylamine (DIPEA) (37 μL) was added at room temperature and stirred for 20 h. The reaction mixture was then added dropwise into cold diethyl ether/MeOH (1:1) (40 mL), and the resultant precipitate was centrifuged (5000 rpm for 5 min), the supernatant was decanted, and the pellet was further washed (three times) and dried under high vacuum afforded the PLGA-b-PEG-COOH (342 mg). The efficiency of the coupling reaction was confirmed by 1 H NMR (Agilent 400 MHz NMR, CDCl 3 ) (SI Figure S1 ). 46 Synthesis of uPAR-Targeted Peptide (uPA) and Scrambled Peptide Conjugated PLGA-b-PEG-COOH Polymers. Peptide conjugation was achieved using Steglich esterification reaction conditions with slight modifications. A solution of synthesized PLGA-b-PEG-COOH copolymer (1 equiv) in dry DMF and targeted peptide sequence (VSNKYFSNIHWGC) (1.5 equiv) in dry DMF (1.5 mL), 4-dimethylaminopyridine (2 equiv) were combined at RT. The reaction mixture was cooled to 0°C using ice base, and 1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide (EDC) (10 equiv) in dry DMF was added to it dropwise and stirred for 10 min. The ice base was removed, and the reaction mixture was stirred at RT for 6 h. The reaction mixture was then added dropwise into cold diethyl ether/MeOH (1:1) (10 mL), and the resultant precipitate was centrifuged (5000 rpm for 5 min), the supernatant was decanted, and the pellet was further washed (three times) to remove the excess free peptide, EDC, dried under a high vacuum, and afforded the PLGA-b-PEG-uPA peptide (88% yield). The efficiency of the peptide conjugation was confirmed by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF-MS) mass spectrometry using AB Sciex 5800 TOF/ TOF System (SI Figure S2) . The scramble peptide sequence (SGLITPGILPIHGCSF) conjugation to PLGA-b-PEG-COOH was achieved using similar procedure.
Formulation of Antisense-miRNAs Loaded PLGA-b-PEG and Peptide Conjugated PLGA-b-PEG NPs. PLGA-b-PEG nanoparticles loaded with antisense-miRNAs/spermidine were formulated by double emulsion solvent evaporation technique with minor modifications. 35, 36 In all coencapsulations 95% antisense-miR-21 with 5% Cy5-antisense-miR-21 was used to maintain the consistency in the formulation across different experiments, and 20% peptide conjugated PLGA-b-PEG and 80% PLGA-b-PEG polymers were used for targeted peptide conjugated nanoparticle synthesis. Antisense-miRNAs (10 nmol) were complexed with spermidine in an N/P ratio of 15:1 at room temperature for 15 min in DNase/RNAase free water. 35, 36 The antisense-miRNAspermidine complex was added dropwise to the stirred solution of PLGA-b-PEG polymer (10 mg) in dichloromethane (1 mL) containing 3% Span-80, followed by sonication for 60 s at 40% amplitude in ice bath to form the first emulsion. To this primary emulsion, 5 mL of emulsifying water (Tween-80, 1% w/v) was added and sonicated at 40% amplitude in ice bath for 60 s to form second emulsion, followed by stirring for 3 h to allow the dichloromethane to evaporate. The NPs were sterile filtered using 0.45 μm syringe filter (Whatman PURADISC 25 AS, PES, GE Healthcare), and excess surfactants and free antisense-miRNAs were removed by an ultracentrifuge filter device with 100 kDa MWCO Membrane (Millipore, USA) by centrifuging at 3000 rpm. The concentrated nanoparticles were washed and centrifuged several times with DNase/RNAase free water (Invitrogen, USA). The concentrated nanoparticles were diluted to a known volume, estimated for their particle size, Zeta potential and the loaded antisense-miRNAs level, prior to use in different experiments.
In Vivo Tumor Growth Studies with PLGA-b-PEG-uPA and Scrambled-uPA NPs. The mouse TNBC xenograft tumor model was developed by injecting 0.1 mL of MDA-MB-231-Fluc-eGFP cell suspension (10 Â 10 6 ) into the left and right flank of a female nude mice (nu/nu) using 50% (v/v) Matrigel. After 15 days, when the tumors grew to 100À300 cubic mm, the animals were randomized and selected for various treatment groups (1: Control-NP, 2: uPA-antisense-miR-21-NP, 3: uPA-antisense-miR-10b-NP, 4: uPAantisense-miR-21 and antisense-mioR-10b-NP and 5: Scrb-uPAantisense-miR-21 and antisense-miR-10b-NP). In each group, 5-animals (total 25 animals) were chosen for treatment. Prior to NPs administration, animals were anesthetized and injected with 100 μL of D-luciferin (30 mg/mL in PBS) via I.P., and assessed by IVIS-Spectrum Imaging system for bioluminescence from tumors. At every time point, tumor volumes were measured and imaged using IVIS Spectrum; after imaging, animals were intravenously administered with control NPs, different antisense-miRNAs loaded NPs on Day 0, Day 3, and Day 6. All animals were also imaged on Day 1, 4, 7, and 9. On Day 9, all animals were sacrificed and tumors were collected for ex vivo histological analysis.
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